Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive

Authors

  • P. Surampudi,

    1. Division of Endocrinology, Department of Medicine, Harbor UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance, CA, USA
    Search for more papers by this author
    • These authors contributed equally to the study.
  • S. T. Page,

    1. Division of Endocrinology, Department of Medicine, University of Washington, Seattle, WA, USA
    Search for more papers by this author
    • These authors contributed equally to the study.
  • R. S. Swerdloff,

    1. Division of Endocrinology, Department of Medicine, Harbor UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance, CA, USA
    Search for more papers by this author
  • J. J. Nya-Ngatchou,

    1. Division of Endocrinology, Department of Medicine, University of Washington, Seattle, WA, USA
    Search for more papers by this author
  • P. Y. Liu,

    1. Division of Endocrinology, Department of Medicine, Harbor UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance, CA, USA
    Search for more papers by this author
  • J. K. Amory,

    1. Division of Endocrinology, Department of Medicine, University of Washington, Seattle, WA, USA
    Search for more papers by this author
  • A. Leung,

    1. Division of Endocrinology, Department of Medicine, Harbor UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance, CA, USA
    Search for more papers by this author
  • L. Hull,

    1. Division of Endocrinology, Department of Medicine, Harbor UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance, CA, USA
    Search for more papers by this author
  • D. L. Blithe,

    1. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
    Search for more papers by this author
  • J. Woo,

    1. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
    Search for more papers by this author
  • W. J. Bremner,

    1. Division of Endocrinology, Department of Medicine, University of Washington, Seattle, WA, USA
    Search for more papers by this author
  • C. Wang

    Corresponding author
    1. Division of Endocrinology, Department of Medicine, Harbor UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance, CA, USA
    • Correspondence:

      Christina Wang, Clinical and Translational Science Institute, Harbor-UCLA Medical Center, 1000 W. Carson St, Torrance, CA 90509, USA.

      E-mail: wang@labiomed.org

    Search for more papers by this author

Summary

The novel androgen, dimethandrolone (DMA) has both androgenic and progestational activities, properties that may maximize gonadotropin suppression. We assessed the pharmacokinetics of dimethandrolone undecanoate (DMAU), an orally bioavailable, longer acting ester of DMA, for male contraceptive development. Our objective was to examine the safety and pharmacokinetics of single, escalating doses of DMAU (powder in capsule formulation) administered orally with or without food in healthy men. We conducted a randomized, double-blind Phase 1 study. For each dose of DMAU (25–800 mg), 10 male volunteers received DMAU and two received placebo at two academic medical centres. DMAU was administered both fasting and after a high-fat meal (200–800 mg doses). Serial serum samples were collected over 24 h following each dose. DMAU was well tolerated without significant effects on vital signs, safety laboratory tests or electrocardiograms. When administered while fasting, serum DMA (active compound) was detectable in only 4/10 participants after the 800 mg dose. When administered with a 50% fat meal, serum DMA was detectable in all participants given 200 mg DMAU and showed a dose-incremental increase up to 800 mg, with peak levels 4–8 h after taking the dose. Serum gonadotropins and sex hormone concentrations were significantly suppressed 12 h after DMAU administration with food at doses above 200 mg. This first-in-man study demonstrated that a single, oral dose of DMAU up to 800 mg is safe. A high-fat meal markedly improved DMAU/DMA pharmacokinetics.

Ancillary